Open-Label, Single-Arm, Phase 3b, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT-199) in Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Mar 2018
At a glance
- Drugs Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms VENICE I
- Sponsors AbbVie
- 07 Mar 2018 Planned End Date changed from 23 Oct 2022 to 5 Mar 2022.
- 07 Mar 2018 Planned primary completion date changed from 23 Oct 2022 to 5 Mar 2022.
- 07 Mar 2018 Status changed from recruiting to active, no longer recruiting.